Search Results - "Clifton, G.T"

2764 Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence by Greene, J.M, Schneble, E.J, Berry, J.S, Trappey, A.F, Clifton, G.T, Darcy, K, Elkas, J.C, Hamilton, C.A, Maxwell, G.L, Peoples, G.E

Get full text

QS149. Monitoring Cytokine Levels to Adjust Dosing and Predict Response to HER/NEU Peptide Based Cancer Vaccines by Clifton, G.T, Benavides, L, Gates, J, Rivera, S, McCall, S, Holmes, J, Mittendorf, E, Merrill, G, Ponniah, S, Peoples, G.E

Get full text

2309P High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment by Dillon, L.A., Sher, X., Gootkind, F.D., Schürpf, T., Berlin, J.D., Clifton, G.T.

Get full text

1732P Cancer-associated fibroblasts correlates with immune phenotypes in human tumors by Italiano, A., J-P. Guegan, Sher, X., Dillon, L.A.L., Schürpf, T., Clifton, G.T.

Get full text

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients by Mittendorf, E.A., Clifton, G.T., Holmes, J.P., Schneble, E., van Echo, D., Ponniah, S., Peoples, G.E.

“…E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2 protein. We have conducted phase I/II…”
Get full text

1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies by Sen, S., Spira, A.I., Sommerhalder, D., Meric-Bernstam, F., Subbiah, V., Berlin, J.D., Parikh, A., Cecchini, M., Sanborn, R.E., Chablani, P.V., Peoples, G.E., Schürpf, T., Dillon, L.A., Clifton, G.T., Eder, J.P., Tolcher, A.W.

Get full text

NCDB analysis of the 8th ajcc gallbladder staging system: validating the T2 subclassification change by Thomas, K., Van Decar, S., Carpenter, E., Adams, A., Smolinsky, T., Chick, R.C., Peoples, G., Clifton, G.T., Vreeland, T.

Get full text

Pre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients by Hale, D.F., Mittendorf, E.A., Brown, T.A., Clifton, G.T., Vreeland, T.J., Myers, J., Peace, K., Jackson, D., Greene, J., Holmes, J., Peoples, G.E.

Get full text

Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression by Jackson, D.O., Peace, K.M., Hale, D.F., Vreeland, T.J., Choy, G., Nejadnik, B., Greene, J.M., Schneble, E.J., Berry, J.S., Trappey, A.F., Hardin, M.O., Clifton, G.T., Herbert, G.S., Mittendorf, E., Holmes, J.P., Peoples, G.E.

Get full text